RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Six Months ended September 30, 2009
Currency: Indian Rupees (Rs.) with U.S. Dollar (U.S.$) convenience translation at Rs.48.09 = U.S.$1.00
Business Overview: DRL is a leading India-based pharmaceutical company operating in three primary segments: Pharmaceutical Services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The company manufactures and markets generic drugs, active pharmaceutical ingredients (APIs), and proprietary products globally.

Key Financial Metrics

Revenue (Six Months Ended Sep 30, 2009): Rs. 36,558 million (U.S.$ 760 million), a 17% increase from Rs. 31,189 million in the prior year period.
Profit for the Period (Six Months): Rs. 4,618 million (U.S.$ 96 million), a 113% increase from Rs. 2,164 million.
Operating Profit (Six Months): Rs. 5,840 million, compared to Rs. 2,883 million in the prior year.
Gross Margin: 51.7% for the six months ended September 30, 2009 (Rs. 18,892 million gross profit on Rs. 36,558 million revenue).
Cash Flow from Operations (Six Months): Net cash inflow of Rs. 9,036 million (U.S.$ 188 million), a significant improvement from a net outflow of Rs. 307 million in the prior year.
Debt and Liquidity:

• Cash and Cash Equivalents: Rs. 6,149 million (U.S.$ 128 million) as of September 30, 2009.
• Short-term Borrowings: Rs. 2,047 million (U.S.$ 43 million).
• Long-term Borrowings (Non-current): Rs. 8,347 million (U.S.$ 174 million).
• Total Debt: Approximately Rs. 12,469 million in long-term loans and borrowings plus short-term borrowings.

Earnings Per Share (Six Months): Basic Rs. 27.40 (U.S.$ 0.57); Diluted Rs. 27.26 (U.S.$ 0.57).

Material Changes vs. Prior Period

Revenue Growth: Driven by a 14% increase in the Global Generics segment (Rs. 25,727 million) and an 11% increase in the PSAI segment (Rs. 10,245 million). North America revenues in Global Generics grew 73% year-over-year, while European revenues declined due to tender impacts in Germany.
Profitability Surge: Net profit more than doubled, primarily due to higher operating income, a significant foreign exchange gain (Rs. 161 million vs. loss of Rs. 120 million), and lower finance costs.
Inventory Write-downs: Significant inventory write-downs of Rs. 814 million were recorded in the six months ended September 30, 2009, compared to Rs. 73 million in the prior year. This was largely due to expiring inventory in German operations and the genericization of sumatriptan in the U.S.
Effective Tax Rate: Increased to 22.25% for the six months ended September 30, 2009, from 12.75% in the prior year, due to higher projected profits in high-tax jurisdictions and the absence of a specific tax benefit from German litigation provisions recorded in the prior year.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Trends:

• Germany: Management expects revenues and profits in Germany to be significantly lower for the fiscal year ending March 31, 2010, due to a shift to a "high volume, low margin" tender-based model. Recent tenders by health insurance funds (AOK, GWQ, Techniker) have resulted in lower price realizations.
• United States: Strong growth expected driven by new product launches (e.g., Sumatriptan, Lotrel, Antara) and a robust pipeline of 140 ANDAs filed with the FDA.
• India: Continued growth anticipated, outpacing the industry average, driven by new product launches and supply chain initiatives.

Risks and Contingencies:

• Patent Litigation: Ongoing disputes regarding Fexofenadine (U.S.), Alendronate Sodium (Germany), and Olanzapine (Canada). While the Canadian court recently ruled the Zyprexa patent invalid, appeals are possible.
• Regulatory Matters: Voluntary recall of four generic products in the U.S. in September 2009 due to oversized tablets; investigations by U.S. state Attorneys General regarding marketing practices.
• Environmental: Pending litigation regarding environmental compensation in India, though additional liability is considered remote.

Unusual Items:

• Restructuring: Rs. 435 million recorded as termination benefits for workforce reduction in German subsidiaries.
• Amalgamation: Tax benefit of Rs. 281 million recognized from the amalgamation of Perlecan Pharma Private Limited.

Key Facts for Investor Verification

• German Market Exposure: Verify the impact of ongoing German health insurance tenders on future margins and revenue stability for the betapharm subsidiary.
• Inventory Valuation: Assess the adequacy of provisions for slow-moving or expiring inventory, particularly in Germany and for specific U.S. products like sumatriptan.
• Patent Litigation Outcomes: Monitor the status of the Fexofenadine litigation in the U.S. and the Olanzapine appeal in Canada, as adverse rulings could result in significant damages or market exclusions.
• Foreign Exchange Sensitivity: Evaluate the company's exposure to currency fluctuations, as the depreciation of the Indian Rupee significantly boosted reported profits in the current period.
• Regulatory Compliance: Review the outcome of the U.S. FDA investigation regarding the September 2009 product recall and any potential penalties or operational restrictions.